CVRx, Inc. filings document a Nasdaq-listed medical device company commercializing Barostim neuromodulation therapy for cardiovascular disease. Its Form 8-K reports record financial results releases, preliminary operating updates, material agreements, equity offering arrangements, amendments to its loan and security agreement, and executive compensation actions tied to performance stock units.
Proxy filings describe annual meeting matters, director elections, auditor ratification, board structure and stockholder voting procedures. The company’s SEC record also identifies its common stock, emerging growth company status, governance disclosures and capital-structure matters associated with debt and at-the-market equity financing.
CVRx, Inc. filed a shelf registration statement on Form S-3 to offer and sell up to $150,000,000 of securities from time to time after effectiveness. The shelf covers common stock, preferred stock, debt securities, stock purchase contracts, warrants, rights, and units, with specific terms to be set in prospectus supplements.
Offerings may be made through underwriters, dealers, agents, or directly, at fixed, market-related, or negotiated prices. Use of proceeds will be described in the applicable supplement. CVRx’s common stock trades on Nasdaq under the symbol CVRX; on November 3, 2025, the last reported sale price was $10.36 per share.
CVRx, Inc. reported third‑quarter results showing steady top‑line growth and improved margins while remaining unprofitable. Revenue for the three months ended September 30, 2025 was $14.7 million, up 10% year over year, driven mainly by U.S. heart failure implants. Gross margin rose to 87% from 83% on higher average selling prices and manufacturing efficiencies.
Operating expenses were $25.0 million, yielding a loss from operations of $12.3 million. Net loss was $12.9 million (basic and diluted net loss per share $0.49). For the nine months, revenue reached $40.6 million (up 13%) with a net loss of $41.4 million.
Cash and cash equivalents were $85.1 million as of September 30, 2025, with $50.0 million of long‑term debt outstanding under the Innovatus loan. The company issued 543,462 shares via its ATM for gross proceeds of $9.5 million during the nine‑month period. CMS finalized the 2026 Medicare Physician Fee Schedule adding Category I CPT codes for Barostim, effective January 1, 2026.
CVRx, Inc. furnished a Form 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The disclosure was made under Item 2.02, and the press release is included as Exhibit 99.1 and incorporated by reference.
The company states this information is being furnished, not filed, under the Exchange Act. CVRx’s common stock trades on the Nasdaq Global Select Market under the symbol CVRX.
Brent Binkowski, Chief Operating Officer of CVRx (CVRX), acquired equity awards on 08/11/2025 that increase his direct stake in the company. He received 16,600 restricted stock units that vest 25% on each anniversary of the grant date, and was granted stock options for 74,900 shares with an exercise price of $7.51. The options vest 25% after one year and then 1/48th per month thereafter and have an expiration date listed as 08/10/2035. Following these transactions, the reporting person directly beneficially owns 16,600 shares and holds options for 74,900 shares.
Brent Binkowski, identified as Chief Operating Officer of CVRx, Inc. (CVRX), submitted an initial Form 3 reporting his relationship to the issuer as an officer. The Form 3 records that no securities are beneficially owned by Mr. Binkowski at the time of the reported event. The filing is an initial ownership disclosure required under Section 16 to report officers' holdings (or lack thereof).